Biovail NDA For New Wellbutrin Formulation Is “Not Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.